“With Asciminib 44% patients achieved response improvement”

2023-06-27 15:21:03

“We collected the data presented at the last European Congress of Hematology, held in Frankfurt, and we were able to observe that, of the 77 patients involved in the analysis, 44% obtained an improvement in response”. These are the words of Massimo Breccia, professor of Hematology at the Umberto I Polyclinic in Rome, on the sidelines of the meeting entitled “New mechanism of action against chronic myeloid leukemia: greater efficacy and tolerability with Asciminib, now also reimbursed in Italy”, promoted by Novartis and held in Milan.